The global radiopharmaceuticals market in nuclear medicine is projected to grow from an estimated value of USD 7.10 billion in 2024 to USD 12.6 billion by 2031, with a compound annual growth rate (CAGR) of 8.5%. This growth is detailed in a recent market intelligence report from CMI titled "Global Radiopharmaceuticals in Nuclear Medicine Market 2024, Growth Opportunities, and Forecast." Key trends highlighted include new PET imaging opportunities expanding diagnostics beyond oncology, strategic partnerships enhancing innovation speed, significant investments in the Asia-Pacific region, market consolidation through mergers and acquisitions, and regulatory challenges in commercialization. The report offers comprehensive market insights, including regional analyses across North America, Europe, Asia-Pacific, South America, and the Middle East & Africa, along with competitive intelligence on major players in the industry such as Progenics Pharmaceuticals and Bayer AG. It emphasizes emerging growth opportunities and strategic considerations for stakeholders in the market.
Thu, 05 Sep 2024 10:43:24 GMT | WhaTech